Canton Biologics announced that it has entered into letter of intent with new investor Shenzhen Weiguang Biological Products Co., Ltd. (SZSE:002880) to receive CNY 30,000,000 in equity round of funding on March 26, 2021. The investor will acquire 6.263% stake in the company. The registered capital of the company will increase by CNY 1,479,700 from CNY 22,146,400 to CNY 23,626,100 upon closing and CNY 28,520,300 will be added in capital reserve. The transaction is subject to approval of board of directors of Shenzhen Weiguang Biological Products Co., Ltd. (SZSE:002880) and does not need its shareholder's approval.